Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010, ...

Taking aim at a longtime target of anti-vaccine activists, CDC advisors said Thursday that the U.S. should not administer ...

The CDC's newly rebuilt Advisory Committee on Immunization Practices (ACIP) took aim Thursday at a mercury-based preservative ...

ABU DHABI, 13th June, 2025 (WAM) -- Abu Dhabi Public Health Centre (ADPHC) has vaccinated nearly 300,000 people across Abu Dhabi, Al Ain Region, and Al Dhafra with the seasonal flu vaccine as part ...

Influenza viruses have infected humans for hundreds of years. The strain that causes Avian Flu was first discovered in China in 1996 and differs from the seasonal flu strains that sicken people.